Tricyclic antidepressant
Tricyclic antidepressant | ||
---|---|---|
Chemical class Tricyclic | | |
External links | ||
MeSH | D000929 | |
Legal status | ||
In Wikidata |
Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade.[1] They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.
Although TCAs are sometimes prescribed for depressive disorders, they have been largely replaced in clinical use in most parts of the world by newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs) and norepinephrine reuptake inhibitors (NRIs). Adverse effects have been found to be of a similar level between TCAs and SSRIs.[2]
History
The TCAs were developed amid the "explosive birth" of psychopharmacology in the early 1950s. The story begins with the synthesis of
The first TCA reported for the treatment of depression was imipramine, a dibenzazepine analogue of chlorpromazine code-named G22355. It was not originally targeted for the treatment of depression. The drug's tendency to induce manic effects was "later described as 'in some patients, quite disastrous'". The paradoxical observation of a sedative inducing mania led to testing with depressed patients. The first trial of imipramine took place in 1955 and the first report of antidepressant effects was published by Swiss psychiatrist Roland Kuhn in 1957.[3] Some testing of Geigy's imipramine, then known as Tofranil, took place at the Münsterlingen Hospital near Konstanz.[4] Geigy later became Ciba-Geigy and eventually Novartis.
Merck introduced the second member of the TCA family, amitriptyline (Elavil), in 1961.[4] This compound has a different three-ring structure than imipramine.
Medical uses
The TCAs are used primarily in the
Nortriptyline and desipramine may be preferred medications over other TCAs among older adults due to their reduced anticholinergic effects, diminished cardiac toxicity, and more linear pharmacokinetics.[8][9]
Clinical depression
For many years the TCAs were the first choice for
Nonetheless, the TCAs are commonly prescribed for
Attention-deficit hyperactivity disorder
The TCAs were used in the past in the clinical treatment of ADHD,
Chronic pain
The TCAs show efficacy in the clinical treatment of a number of different types of
Side effects
Many
Other side effects may include drowsiness, anxiety, emotional blunting (apathy/
Tolerance to these adverse effects of these drugs often develops if treatment is continued. Side effects may also be less troublesome if treatment is initiated with low doses and then gradually increased, although this may also delay the beneficial effects.
TCAs can behave like class 1A antiarrhythmics, as such, they can theoretically terminate ventricular fibrillation, decrease cardiac contractility and increase collateral blood circulation to ischemic heart muscle. Naturally, in overdose, they can be cardiotoxic, prolonging heart rhythms and increasing myocardial irritability.
New research has also revealed compelling evidence of a link between long-term use of anticholinergic medications like TCAs and dementia.[25] Although many studies have investigated this link, this was the first study to use a long-term approach (over seven years) to find that dementias associated with anticholinergics may not be reversible even years after drug use stops.[26] Anticholinergic drugs block the action of acetylcholine, which transmits messages in the nervous system. In the brain, acetylcholine is involved in learning and memory.
Discontinuation
Antidepressants in general may produce withdrawal. However, since the term "withdrawal" has been linked to addiction to recreational drugs like opioids, the medical profession and pharmaceutical public relations prefer that a different term be used, hence "discontinuation syndrome."[27] Discontinuation symptoms can be managed by a gradual reduction in dosage over a period of weeks or months to minimise symptoms.[28] In tricyclics, discontinuation syndrome symptoms include anxiety, insomnia, headache, nausea, malaise, or motor disturbance.[29]
Overdose
TCA overdose is a significant cause of fatal drug
A number of treatments are effective in a TCA overdose.
An overdose on TCA is especially fatal as it is rapidly absorbed from the GI tract in the alkaline conditions of the small intestines. As a result, toxicity often becomes apparent in the first hour after an overdose. However, symptoms may take several hours to appear if a mixed overdose has caused delayed gastric emptying.
Many of the initial signs are those associated to the anticholinergic effects of TCAs such as dry mouth, blurred vision, urinary retention, constipation, dizziness, and emesis (or vomiting). Due to the location of norepinephrine receptors all over the body, many physical signs are also associated with a TCA overdose:[31]
- Anticholinergic effects: altered mental status (e.g., agitation, confusion, lethargy, etc.), resting sinus tachycardia, dry mouth, mydriasis, blurred vision, fever
- Cardiac effects: hypertension (early and transient, should not be treated), tachycardia, orthostasis and hypotension, arrhythmias (including ECGchanges (prolonged QRS, QT, and PR intervals)
- CNS effects: syncope, seizure, coma, myoclonus, hyperreflexia, convulsions, drowsiness
- Pulmonary effects: hypoventilation resulting from CNS depression[32]
- Gastrointestinal effects: decreased or absent bowel sounds
Treatment of TCA overdose depends on severity of symptoms:
Initially, gastric decontamination of the patient is achieved by administering, either orally or via a
If there is metabolic acidosis, intravenous infusion of sodium bicarbonate is recommended by Toxbase.org, the UK and Ireland poisons advice database (TCAs are protein bound and become less bound in more acidic conditions, so by reversing the acidosis, protein binding increases and bioavailability thus decreases – the sodium load may also help to reverse the Na+ channel blocking effects of the TCA).
Interactions
The TCAs are highly metabolised by the
Pharmacology
The majority of the TCAs act primarily as SNRIs by blocking the
In addition to their
Most, if not all, of the TCAs also
In summary, tricyclic antidepressants can act through NMDA antagonism, opioidergic effects, sodium, potassium and calcium channel blocking, through interfering with the reuptake of serotonin and acting as antagonists to SHAM (serotonin, histamine, alpha, muscarinic) receptors. Thus their dangerous side effect profile limits their use in daily practice.
Binding profiles
The binding profiles of various TCAs and some
Compound | SERT | NET | DAT | 5-HT1A | 5-HT2A | 5-HT2C | 5-HT6 | 5-HT7 | α1 | α2 | D2 |
H1 |
H2 |
mACh | σ1 | σ2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amineptine | >100,000 | 10,000 | 1,000–1,400 | >100,000 | 74,000 | ND | ND | ND | >100,000 | >100,000 | >100,000 | ≥13,000 | ND | >100,000 | ND | ND |
Amitriptyline | 2.8–4.3 | 19–35 | 3,250 | ≥450 | 18–23 | 4.0 | 65–141 | 93–123 | 4.4–24 | 114–690 | 196–1,460 | 0.5–1.1 | 66 | 9.6 | 300 | ND |
Amoxapine | 58 | 16 | 4,310 | ND | 0.5 | 2.0 | 6.0–50 | 41 | 50 | 2,600 | 3.6–160 | 7.9–25 | ND | 1,000 | ND | ND |
Butriptyline | ≥1,360 | 5,100 | 3,940 | 7,000 | 380 | ND | ND | ND | 570 | 4,800 | ND | 1.1 | ND | 35 | ND | ND |
Clomipramine | 0.14–0.28 | 38–54 | ≥2,190 | ≥7,000 | 27–36 | 65 | 54 | 127 | 3.2–38 | ≥535 | 78–190 | 13–31 | 209 | 37 | 546 | ND |
Desipramine | 18–163 | 0.63–3.5 | 3,190 | ≥6,400 | 115–350 | 244–748 | ND | >1,000 | 23–130 | ≥1,379 | 3,400 | 60–110 | 1,550 | 66–198 | ≥1,990 | ≥1,610 |
Dibenzepin | ND | ND | >10,000 | >10,000 | ≥1,500 | ND | ND | ND | >10,000 | >10,000 | >10,000 | 23 | 1,950 | 1,750 | ND | ND |
Dosulepin | 8.6–78 | 46–70 | 5,310 | 4,000 | 152 | ND | ND | ND | 419 | 2,400 | ND | 3.6–4.0 | ND | 25–26 | ND | ND |
Doxepin | 68–210 | 13–58 | ≥4,600 | 276 | 11–27 | 8.8–200 | 136 | ND | 24 | 28–1,270 | 360 | 0.09–1.23 | 174 | 23–80 | ND | ND |
Imipramine | 1.3–1.4 | 20–37 | 8,500 | ≥5,800 | 80–150 | 120 | 190–209 | >1,000 | 32 | 3,100 | 620–726 | 7.6–37 | 550 | 46 | 332–520 | 327–2,100 |
Iprindole | ≥1,620 | 1,260 | 6,530 | 2,800 | 217–280 | 206 | ND | ND | 2,300 | 8,600 | 6,300 | 100–130 | 200–8,300 | 2,100 | >10,000 | ND |
Lofepramine | 70 | 5.4 | >10,000 | 4,600 | 200 | ND | ND | ND | 100 | 2,700 | 2,000 | 245–360 | 4,270 | 67 | 2,520 | ND |
Maprotiline | 5,800 | 11–12 | 1,000 | ND | 51 | 122 | ND | 50 | 90 | 9,400 | 350–665 | 0.79–2.0 | 776 | 570 | ND | ND |
Norclomipramine | 40 | 0.45 | 2,100 | 19,000 | 130 | ND | ND | ND | 190 | 1,800 | 1,200 | 450 | ND | 92 | ND | ND |
Northiaden | 192 | 25 | 2,539 | 2,623 | 141 | ND | ND | ND | 950 | ND | ND | 25 | ND | 110 | ND | ND |
Nortriptyline | 15–18 | 1.8–4.4 | 1,140 | 294 | 5.0–41 | 8.5 | 148 | ND | 55 | 2,030 | 2,570 | 3.0–15 | 646 | 37 | 2,000 | ND |
Opipramol | ≥2,200 | ≥700 | ≥3,000 | >10,000 | 120 | ND | ND | ND | 200 | 6,100 | 120–300 | 6.0 | 4,470 | 3,300 | 0.2–50 | 110 |
Protriptyline | 19.6 | 1.41 | 2,100 | 3,800 | 70 | ND | ND | ND | 130 | 6,600 | 2,300 | 7.2–25 | 398 | 25 | ND | ND |
Tianeptine | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 |
Trimipramine | 149–2,110 | ≥2,450 | ≥3,780 | 8,000 | 32 | 537 | ND | ND | 24 | 680 | 143–210 | 0.27–1.5 | 41 | 58 | ND | ND |
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. For assay species and references, see the individual drug articles. Most but not all values are for human proteins. |
With the exception of the
Therapeutic levels of TCAs are generally in the range of about 100 to 300 ng/mL, or 350 to 1,100 nM.[53] Plasma protein binding is generally 90% or greater.[53]
Chemistry
There are two major groups of TCAs in terms of
In addition to classification based on the ring system, TCAs can also be usefully grouped based on the number of
Society and culture
Recreational use
A very small number of cases involving non-medical use of antidepressants have been reported over the past 30 years.[60] According to the US government classification of psychiatric medications, TCAs are "non-abusable"[61] and generally have low misuse potential.[62] Nonetheless, due to their atypical mechanism of action, amineptine and tianeptine (dopamine reuptake inhibition and μ-opioid receptor agonism, respectively) are the two TCAs with the highest addiction and misuse potential. Several cases of the misuse[63] of amitriptyline alone[64][65] or together with methadone[63][66] or in other drug dependent patients[67][68] and of dosulepin with alcohol[69] or in methadone patients[70] have been reported.
List of TCAs
Those that preferentially inhibit the reuptake of serotonin (by at least 10-fold over norepinephrine) include:
- Butriptyline† (Evadyne) (relatively weak serotonin reuptake inhibitor)
- Clomipramine (Anafranil)
- Imipramine (Tofranil, Janimine, Praminil)
- Trimipramine (Surmontil) (relatively weak serotonin reuptake inhibitor)
Those that preferentially inhibit the reuptake of norepinephrine (by at least 10-fold over serotonin) include:
- Desipramine (Norpramin, Pertofrane)
- Dibenzepin‡ (Noveril, Victoril)
- Lofepramine§ (Lomont, Gamanil)
- Maprotiline (Ludiomil) – can be classed with the TCAs though more frequently classed with the TeCAs
- Nortriptyline (Pamelor, Aventyl, Norpress)
- Protriptyline (Vivactil)
Whereas either fairly balanced reuptake inhibitors of serotonin and norepinephrine or unspecified inhibitors include:
- Amitriptyline (Elavil, Endep)
- Amitriptylinoxide (Amioxid, Ambivalon, Equilibrin)
- Amoxapine (Asendin) – can be classed with the TeCAs but more frequently classed with the TCAs
- Demexiptiline† (Deparon, Tinoran)
- Dimetacrine† (Istonil, Istonyl, Miroistonil)
- Dosulepin§ (Prothiaden)
- Doxepin (Adapin, Sinequan)
- Fluacizine† (Phtorazisin)
- Imipraminoxide† (Imiprex, Elepsin)
- Melitracen§ (Deanxit, Dixeran, Melixeran, Trausabun)
- Metapramine† (Timaxel)
- Nitroxazepine‡ (Sintamil)
- Noxiptiline‡ (Agedal, Elronon, Nogedal)
- Pipofezine‡ (Azafen/Azaphen)
- Propizepine† (Depressin, Vagran)
- Quinupramine† (Kevopril, Kinupril, Adeprim, Quinuprine)
And the following are TCAs that act via main mechanisms other than serotonin or norepinephrine reuptake inhibition:
- Amineptine‡ (Survector, Maneon, Directim) – norepinephrine–dopamine reuptake inhibitor
- Iprindole† (Prondol, Galatur, Tetran) – 5-HT2 receptor antagonist
- agonist
- Tianeptine § (Stablon, Coaxil, Tatinol) – atypical μ-opioid receptor agonist
Legend:
- † indicates products which have been withdrawn from the market worldwide.
- ‡ indicates products which are not available in any country in which English is an official language.
- § indicates products which are not available in the United States, but are available in other English-speaking countries such as Australia, Canada, United Kingdom, etc.
- Bolded names indicates products which are available in at least three countries in which English is an official language.
See also
References
- ISBN 978-0-7216-8053-8. pp. 423
- PMID 9861221.
- ^ a b A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs, D. G. Cunningham Owens, http://assets.cambridge.org/97805216/33536/excerpt/9780521633536_excerpt.pdf
- ^ ISBN 978-0-7658-0224-8.
- ^ "Nonstimulant Therapy (Strattera) and Other ADHD Drugs - MedicineNet". MedicineNet. Archived from the original on 2016-03-05. Retrieved 2014-11-19.
- S2CID 12016207.
- PMID 26789925.
- PMID 32491723, retrieved 2023-10-08
- PMID 17471183.
- PMID 7980178.
- PMC 10806869.
- PMID 10498158.
- S2CID 36366654.
- PMID 2676967.
- PMID 19183781.
- S2CID 45497168.
- PMID 9418743.
- PMID 16762426.
- S2CID 25124663.
- S2CID 40631429.
- S2CID 22957748.
- PMID 9706370.
- ^ Gelder, M, Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp243.
- PMID 16846511.
- PMID 25621434.
- ^ "Strong Link Found Between Dementia, Common Anticholinergic Drugs". Drug Discovery & Development.
- PMID 16683856.
- S2CID 14286356.
- ^ Kent Kunze MD. "Somatic Therapies in Psychiatry". Des Moines University Psychiatry Class.[permanent dead link]
- PMID 15707813.
- ^ California Poison Control 1-800-876-4766
- S2CID 22653093.
- ^ "Clinical Pharmacology of SSRI's: Why Are CYP Enzymes Important When Considering SSRIs?". preskorn.com.
- ^ PMID 9537821.
- PMID 17471183.
- S2CID 8093564.
- ^ S2CID 21236268.
- ^ S2CID 19490821.
- PMID 10836139.
- S2CID 7965330.
- PMID 2568580. Archived from the originalon 2021-08-29. Retrieved 2009-07-10.
- ^ PMID 8831113.
- S2CID 260238757.
- ^ "Differences between tricyclic antidepressants and SNRIs mechanism of action | Pharmacology Corner". 28 April 2010.
- S2CID 1153522.
- PMID 6150708.
- PMID 19721108.
- PMID 9435180. Archived from the originalon 2021-08-29. Retrieved 2009-07-20.
- S2CID 24777.
- PMID 10452441.
- ISBN 978-0-470-52221-9.
- ^ Roth, BL, Driscol, J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
- ^ ISBN 978-1-58562-309-9.
- ^ ISBN 978-1-4899-3436-9.
- ^ ISBN 978-0-444-53266-4.
- ^ ISBN 978-1-56053-470-9.
- ^ ISBN 978-0-19-162675-3.
- ISBN 978-1-58562-523-9.)
{{cite book}}
: CS1 maint: multiple names: authors list (link - S2CID 235610556.
- ISBN 978-0-85369-582-0.
- National Library of Medicine. Retrieved 2007-05-25.
- National Library of Medicine. Retrieved 2007-05-25.
- ^ ISBN 978-0-85369-582-0.
- PMID 8456167.
The patient denied any alcohol or substance abuse, and no signs of withdrawal were noted in the hospital...On examination, Ms. B. denied suicidal ideation or intent but did admit to taking over 800 mg of amitriptyline per day for the past 3 years after being started on the drug for depression. She clearly described a euphoria associated with amitriptyline, noting that it gave her a "buzz" and that she felt "numbed up" and calm about 30 minutes after ingestion. The patient expressed fears of being addicted to the amitriptyline and desired inpatient hospitalization for medication adjustment and education.
- PMID 15226578.
- PMID 682328.
- PMID 2400006.
Ms. A, a 24-year-old abuser of alcohol and cannabis, consulted her family physician because of anxiety, depression, and insomnia. Unaware of her drug abuse, he prescribed amitriptyline, 200 mg. About 30 minutes after taking each dose, she would experience relief from her symptoms that lasted about 2 hours. By increasing the dose, she found she could intensify these effects and prolong them for up to several hours. Her "high" consisted of feelings of relaxation, giddiness, and contentment.Frequently, this progressed to incoordination, slurred speech, and confusion. Sometimes she would forget how much she had taken and ingest up to 2 g.
- PMID 16225078.
- PMID 17567406.
- PMID 8520352.
Further reading
- Gillman PK (July 2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated". British Journal of Pharmacology. 151 (6): 737–748. PMID 17471183.
External links
- Tricyclic+Antidepressive+Agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH)